Eltrombopag ITP denied for failing step therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for eltrombopag itp are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Issues a Step-Therapy Denial for Eltrombopag in ITP

A step-therapy denial — sometimes called "fail-first" — means UHC requires documentation that the patient has tried and failed one or more specified earlier treatments before it will approve eltrombopag. For ITP, UHC's policy typically requires evidence of prior treatment with first-line therapies (most commonly corticosteroids) and potentially second-line agents, depending on the version of the policy in force at the time of the request. When prior-authorization documentation does not clearly address each required step, or when the prior therapy history is incomplete or undated, the plan will issue this denial even if the patient has in fact been through appropriate prior treatment.

## Why This Denial Is Appealable

Step-therapy protocols must have a clinically valid exception pathway. Under ACA §2719 and state step-therapy laws (which often impose stricter requirements than federal law), plans must grant exceptions when the required step has been tried and failed, is contraindicated, or would cause clinically significant harm. Under ERISA §503, employer-plan members are entitled to a full-and-fair review. Internal appeal must typically be filed within 180 days of the denial. External review is generally available within 4 months of a final internal denial. Expedited review is available when the patient's condition is urgent and waiting for standard review would be harmful.

## Concrete Appeal Steps

1. Obtain the UHC step-therapy policy: Request the current clinical coverage policy that governs eltrombopag or TPO-RAs in ITP. The policy will list every required step in order. 2. Map your patient's history to each step: For each step the policy requires, identify the corresponding treatment in the patient's chart — drug name, start date, duration, response, and reason for stopping. 3. Submit an internal appeal with a structured point-by-point response to every step requirement. 4. Request a step-therapy exception if the required step was not taken because it is clinically contraindicated — document the contraindication explicitly. 5. Escalate to external review if the internal appeal is denied.

## Documentation to Gather

• Complete ITP treatment timeline: a chronological list of all ITP therapies, including corticosteroids, IVIG, anti-D (if applicable), rituximab, and any surgical intervention, with dates of initiation, duration, response (platelet counts), and reason for discontinuation.
• Contraindication documentation (if applicable): if a required step-therapy agent cannot be used for this patient, the prescriber must document the specific clinical reason in the chart and in the appeal letter.
• Prescriber medical-necessity letter: the treating hematologist should walk through the treatment history step by step, address each policy requirement by name, and state clearly that the patient has either met each step or qualifies for an exception.
• Platelet count history: serial labs showing the inadequacy of prior treatments.

## Criteria-Mapping Structure

| Step Required by UHC Policy | Patient's Documented History | |---|---| | Step 1: [First-line therapy per policy] | [Drug, start date, duration, peak platelet response, reason stopped] | | Step 2: [Second-line therapy per policy, if required] | [Drug, start date, duration, response, reason stopped] | | Exception basis (if step not completed) | [Prescriber-documented contraindication or clinical reason] |

Always pull the current UHC clinical coverage policy for TPO-RAs in ITP — step requirements change with policy revisions. Cross-reference the FDA-approved prescribing label for eltrombopag to ensure the clinical rationale for skipping a step (if applicable) is anchored in recognized clinical guidance.